Relapsed Pediatric ALL Clinical Trial
Official title:
A Multi-center Prospective Clinical Study in China Using CliniMACS TCRα/β+ and CD45RA+ T Cell Depleted Stem Cell Grafts From Haploidentical Donors for Hematopoietic Stem Cell Transplantation in Children With Leukemia
This is a multi-center clinical study in China using CliniMACS TCRα/β+ and CD45RA+ T cell depleted stem cell grafts from haploidentical donors for hematopoietic stem cell transplantation in children.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | May 8, 2024 |
Est. primary completion date | July 18, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Months to 18 Years |
Eligibility | Inclusion Criteria: Pediatric patients with hematological malignancies in complete remission (CR), partial remission (PR) or with stable disease - Acute myeloid leukemia (AML): Patients with high-risk AML in CR1 Patients with relapsed or primary therapy-refractory AML - Acute lymphoid leukemia (ALL): Patients with high-risk ALL in CR1 Patients with relapsed or primary refractory ALL Exclusion Criteria: - Age >18 years or <8 weeks - Patients with progressive disease prior HCT - <3 months after preceding hematopoietic cell transplantation (HCT) - History of neurological impairment (active seizures, severe peripheral neuropathy, signs of leukencephalopathy, active CNS infection) - Fungal infections with radiological and clinical progression - Liver function abnormalities with bilirubin >2 mg/dL and elevation of transaminases higher than 400 U/L - Chronic active viral hepatitis - Ejection fraction <40% or shortening fraction <25% on echocardiography - Patients with > grade II hypertension by Common Toxicity Criteria (CTC) - Creatinine clearance below threshold defined for stem cell transplantation according to local clinical standard - Respiratory failure necessitating supplemental oxygen - HIV infection - Concurrent severe or uncontrolled medical disease (e.g. uncontrolled diabetes, congestive heart failure, myocardial infarction within 6 months prior to the study, unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled infection) which by assessment of the treating physician could compromise participation in the study - Patients with a history of psychiatric illness or a condition which could interfere with their ability to understand the requirements of the study (this includes alcoholism/drug addiction) - Patients unwilling or unable to comply with the protocol or unable to give informed consent - Treatment with any investigational product within 4 weeks prior to study treatment (transfusion of the IMP) |
Country | Name | City | State |
---|---|---|---|
China | Shanghai Children's Medical Center | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shanghai Children's Medical Center | Children's Hospital Of Soochow University, Chinese University of Hong Kong, Miltenyi Biomedicine GmbH, Nanfang Hospital of Southern Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Log number of In Vitro T cells depletion | Log number of In Vitro T cells depletion using CliniMACS TCRab/CD45RA system. | One week | |
Primary | Incidence of grade II-IV acute GVHD | Incidence of grade II-IV acute graft-versus-host disease (GVHD) until Day 100 post-transplantation. | up to 3 months | |
Secondary | Grade I aGVHD | Incidence of grade I acute GVHD until Day 100 post-transplantation | up to 3 months | |
Secondary | cGVHD | Incidence and severity of chronic GVHD in 1 year and 2 years | 2 years | |
Secondary | NRM | Incidence of NRM at all visits throughout the study | 1 year | |
Secondary | Graft failure | incidence of Graft failure from Day 0 to Day 28 | 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04888468 -
Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
|
Phase 1 | |
Completed |
NCT04562792 -
Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia
|
Phase 2 | |
Terminated |
NCT00439296 -
ABT-751 With Chemotherapy for Relapsed Pediatric ALL
|
Phase 1/Phase 2 | |
Recruiting |
NCT03938987 -
Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05334823 -
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
|
Phase 2 |